Insider Buying: TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Acquires $26,156.92 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela acquired 4,826 shares of the firm’s stock in a transaction dated Monday, January 27th. The shares were purchased at an average price of $5.42 per share, with a total value of $26,156.92. Following the acquisition, the chief executive officer now owns 429,503 shares of the company’s stock, valued at approximately $2,327,906.26. This represents a 1.14 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

TriSalus Life Sciences Price Performance

Shares of NASDAQ TLSI opened at $5.11 on Friday. The company has a market capitalization of $155.82 million, a PE ratio of -2.05 and a beta of 0.51. The stock’s 50 day moving average price is $4.59 and its 200-day moving average price is $4.75. TriSalus Life Sciences, Inc. has a twelve month low of $3.50 and a twelve month high of $10.42.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Walleye Capital LLC bought a new stake in shares of TriSalus Life Sciences during the 3rd quarter worth $66,000. Virtu Financial LLC purchased a new stake in TriSalus Life Sciences during the third quarter worth about $92,000. Vestcor Inc bought a new stake in TriSalus Life Sciences in the third quarter worth about $108,000. MSD Partners L.P. purchased a new position in TriSalus Life Sciences in the third quarter valued at about $184,000. Finally, Geode Capital Management LLC grew its position in shares of TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after acquiring an additional 62,542 shares during the period. Hedge funds and other institutional investors own 2.58% of the company’s stock.

Wall Street Analyst Weigh In

TLSI has been the subject of a number of recent research reports. Canaccord Genuity Group decreased their price target on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Northland Securities initiated coverage on shares of TriSalus Life Sciences in a research report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target on the stock. Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Finally, Cantor Fitzgerald initiated coverage on TriSalus Life Sciences in a report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $11.79.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.